Related Story

Akero's $AKRO Stock Surges 100% on Positive MASH Cirrhosis Results, Boosts $ETNB
Akero Therapeutics Inc. ($AKRO) has reported preliminary topline results from its Phase 2b SYMMETRY study, showing a statistically significant reversal of compensated cirrhosis (F4) due to metabolic-associated steatohepatitis (MASH) at Week 96. The study demonstrated a 24-point difference in liver fibrosis improvement, with 39% of patients on efruxifermin showing improvement compared to 15% on placebo. Both completer and intent-to-treat (ITT) analyses indicated a statistically significant outcome, with the ITT analysis showing a 17% improvement over the expected 10%. The positive results have led to a significant pre-market increase in Akero's stock, trading 100% higher. The success of Akero's study is also seen as beneficial for competitors like 89bio Inc. ($ETNB), with its stock also experiencing gains, reaching up to $12.
Proposed Market

Percentage increase in Akero stock by end of 2025?
Description
Stock price data from financial market platforms like NASDAQ or Bloomberg
Market Options
Related Polymarket Markets
No similar markets found
This could indicate a unique market opportunity that hasn't been explored yet.